Neurocrine Biosciences, Inc.

+1.64 (+2.03%)
Products, Strategic Combinations

Neurocrine Biosciences And Sosei Heptares Announce Collaboration To Develop Novel Muscarinic Receptor Agonists For Schizophrenia And Other Neuropsychiatric Disorders

Published: 11/22/2021 17:05 GMT
Neurocrine Biosciences, Inc. (NBIX) - Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders.
Neurocrine Biosciences Inc - Sosei Heptares Receives Us$100 Million Upfront.
Neurocrine Biosciences - Deal for Up to Us$2.6 Billion in Potential Development, Regulatory and Commercial Milestone Payments, Plus Tiered Sales Royalties.
Neurocrine Biosciences Inc - Anticipates Initiating a Phase 2 Study With Selective M4 Agonist Htl-0016878 in Schizophrenia in 2022.
Neurocrine Biosciences Inc - Anticipates Phase 1 Studies for a Dual M1/m4 and Selective M1 Agonist in 2023.
Neurocrine Biosciences - Will Be Responsible for Development Costs Associated With Programs Globally, Except for M1 Agonists Being Developed in Japan.